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Abstract
Objective—Several genetic risk variants for ankylosing spondylitis (AS) have been identified in
genome wide association studies. Our objective was to examine whether familial AS cases have a
higher genetic load of these susceptibility variants.
Methods—Overall, 502 AS patients were examined, consisting of 312 who had first-degree
relatives (FDR) with AS (familial) and 190 who had no FDR with AS or spondyloarthritis
(sporadic). All patients and affected FDRs fulfilled the modified New York Criteria for AS. The
patients were recruited from two U.S. cohorts (NASC and PSOAS) and from the United
Kingdom- Oxford cohort. The frequencies of AS susceptibility loci in IL23R, IL1R2, ANTRX2,
ERAP1, two intergenic regions on chromosomes 2p15 and 21q22, and HLA-B27 status as
determined by the tag SNP rs4349859 were compared between familial and sporadic cases.
Association between SNPs and multiplex status was assessed by logistic regression controlling for
sibship size.
Results—HLA-B27 was significantly more prevalent in familial than sporadic cases of AS
(p=0.0001, OR: 4.44, CI: (2.06–9.55)). Furthermore, the AS risk allele at chromosome 21q22
intergenic region showed a trend towards higher frequency in the multiplex cases (p=0.08). The
frequency of the other AS risk variants did not differ significantly between familial and sporadic
cases, either individually or combined.
Conclusions—HLA-B27 is more prevalent in familial than sporadic cases of AS, demonstrating
higher familial aggregation of AS in patients with HLA-B27 positivity. The frequency of the
recently described non-MHC susceptibility loci is not markedly different between the sporadic and
familial cases of AS.
Introduction
Ankylosing spondylitis (AS) is a chronic inflammatory disorder primarily affecting the
spine, peripheral joints and entheses. Extra-articular features can affect the eye, heart, and
gastrointestinal tract. AS can also occur in the setting of other spondyloarthritides (SpA),
including psoriatic arthritis, reactive arthritis, and enteropathic arthritis. Genetic factors
provide over 90% of the overall susceptibility to AS. AS occurs in up to 75% of
monozygotic twins compared to 27% in HLA-B27 positive dizygotic twins, indicating that
there is a substantial non-MHC genetic component underlying disease (1). Up to half of the
genetic contribution has been attributed to HLA-B27 and possibly other major
histocompatibility complex (MHC) genes. Several non-MHC genes, specifically in the
endoplasmic reticulum aminopeptidase-1(ERAP1), interleukin 23 receptor (IL23R), the
interleukin 1 receptor-2 (IL1R2), and the anthraxin receptor 2 (ANTRX2), as well as two
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intergenic regions at the chromosomes 2 and 21, have been reported as AS susceptibility loci
in genome-wide association studies (2;3).
There are several reports of familial aggregation in AS and SpA. The risk of developing AS
is up to 21% in HLA-B27 positive first degree relatives (FDRs) of AS cases while this risk
decreases to less than 1% in HLA-B27 negative FDRs (4). Furthermore, only 6% of HLA-
B27 positive subjects in the general population develop AS (5), underscoring the importance
of other genetic loci beyond HLA-B27 in contributing to risk of AS. The frequencies of the
above mentioned novel AS susceptibility loci in familial cases in comparison to sporadic AS
cases have not been previously reported.
In the current study, we hypothesized that genetic susceptibility variants will be enriched in
familial as compared to sporadic cases of AS. Therefore, we examined the genotype
frequency of AS susceptibility loci in IL23R, IL1R2, ANTRX2, ERAP, two intergenic
regions at the chromosomes 2 and 21, in addition to a recently described HLA-B27 tag
single-nucleotide polymorphism (SNP) in familial and sporadic cases.
Methods
Familial or multiplex AS was defined as more than one family member (parent, sister,
brother only - offspring were excluded for this study) with confirmed diagnosis of AS.
Singleton or sporadic was defined as only one family member with confirmed AS and no
other reported FDRs with AS or SpA. All index cases and FDRs with AS fulfilled the
modified New York criteria for AS(6). The investigated cohorts included the North
American Spondylitis Consortium (NASC), Prospective Study of Outcomes in Ankylosing
Spondylitis (PSOAS), and United Kingdom- Oxford (UK-Oxford) cohorts.
NASC is a collaboration of eight sites in US cities (Houston, TX; Los Angeles, CA;
Portland, OR; Cleveland, OH; Minneapolis, MN; Philadelphia, PA; Salt Lake City, UT; and
Tampa, FL) as well as the Spondylitis Association of America (SAA), and two sites in
Canada (Toronto, ON and Edmonton, AB), examining multiplex families with AS (7).
NASC patients included families with 2 or more FDRs meeting the modified 1984 New
York criteria for AS and for whom radiographs were available to confirm the diagnosis. The
diagnoses were reevaluated by rheumatologists with experience in assessing patients with
AS and the radiographs were assessed by study investigators.
The PSOAS study is an ongoing, longitudinal study of AS patients from four sites in the US:
Cedars-Sinai Medical center, Los Angeles; the University of Texas at Houston; the
University of California, San Francisco; and the National Institute of Health, Bethesda (8).
Multiplex and singleton AS cases were enrolled in this study. The presence of sacroiliitis on
pelvic radiographs was confirmed by a musculoskeletal radiologist.
The UK-Oxford study is an ongoing cross-sectional genetic study of multicase and sporadic
AS cases in which in all cases the diagnosis of AS had been confirmed by a qualified
rheumatologist. To further confirm the diagnosis, all cases were interviewed by telephone by
study investigators. In patients with atypical medical history or for whom radiographs had
not been performed previously, pelvic and lumbosacral spine radiographs were obtained and
attending physicians were contacted to confirm the diagnosis(9). In this study, all affected
siblings per self-report were assessed according to the above mentioned methodology.
All investigated patients in the current study were of self-reported white European descent.
Only multiplex AS cases with confirmed affected FDR (parent and siblings only) and
singleton AS cases were investigated. Only one patient with AS per family was included in
the analysis.
Joshi et al. Page 2
Arthritis Care Res (Hoboken). Author manuscript; available in PMC 2013 May 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
The following non-MHC susceptibility variants for AS were investigated in the current
study: IL23R, rs11209026; IL1R2, rs2310173; ANTXR2, rs4333130; ERAP1, rs27434; and
two gene desert loci, rs10865331 and rs2242944(2;3). In addition, HLA-B27 was studied
using the findings of a recently described HLA-B27 tag SNP, rs4349859(10). The genotype
information was obtained from a previously described genome-wide association study
conducted in patients enrolled in the NASC, PSOAS and UK-Oxford cohorts(2).
In addition, the clinical features of singleton AS cases in the PSOAS cohort were compared
to the multiplex cases in the UK-Oxford cohort. The information on time of disease onset
was not available in the NASC cohort. Therefore, patients enrolled in the NASC study were
not included in the comparison of clinical features (Table 1).
Statistical Analysis
Association between SNPs and multiplex status was assessed by logistic regression
assuming an additive effect of alleles on log odds of being from a multiplex family.
Individuals from multiplex families were coded as cases and individuals from simplex
families were coded as controls. Best guess genotypes at rs4349859 were imputed using the
software MACH(11) as described in Evans et al. (10). Quality control metrics indicated that
this SNP could be imputed with a high degree of certainty (RSQR > 0.98). Imputed
genotypes at rs4349859 were only available for 292 multiplex and 177 sporadic cases of AS.
In order to minimize the effect of possibly misclassifying multiplex cases from smaller
families as sporadic cases, we examined the effect of adding sibship size as a covariate in
the logistic regression model.
In order to ensure that our results were robust to the effect of population stratification, we
also examined the effect of including Eigenstrat derived principal components from a
previous genome-wide association study of AS in our analysis (2) and restricting our
analysis to US cases only (128 multiplex cases and 176 sporadic cases).
The relationship between the number of affected siblings per family and the number of
HLA-B27 alleles in the index case was examined in the UK-Oxford cohort by linear
regression.
Results
In the current study, 312 unrelated multiplex and 190 singleton AS patients were
investigated. In detail, 160 multiplex AS cases were recruited from the UK-Oxford cohort,
on whom the required genotype data were available. These patients had a mean age (SD) of
47.9 (10.2) at enrollment and 60% were male. The mean disease duration at the enrolment
was 24.9 (11) years. We also recruited 152 multiplex AS cases from the NASC study. In this
group, the mean age at enrollment was 44.4 (10.4) years, 58% of patients were male.
Furthermore, 190 singleton cases were recruited from the PSOAS. This patient group had a
mean age of 47.1 (16.1) years, was 76% male, and had a mean disease duration of 22.8
(15.7) years at enrollment. Table 1 shows the comparison of clinical features between the
singleton and multiplex AS cases. The familial cases had a lower percentage of male
patients (p=0.0004). The other clinical features did not differ significantly between the
singleton and multiplex cases
Table 2 shows the frequency of susceptibility loci in the multiplex and singleton cases.
HLA-B27 was significantly more prevalent in multiplex than in singleton AS cases
(p=8.4×10−8, OR: 5.41, CI (2.92–10.03)). The frequency of the other AS susceptibility loci
in IL23R, IL1R2, ANTXR2, ERAP1 genes and the chromosome 2p15 and 21 q22 intergenic
regions did not differ significantly between the singleton and multiplex cases. Furthermore,
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gender did not modify the significant relationship between HLA-B27 and occurrence of
familial AS (p-value for the interaction term between gender and HLA-B27= 0.763).
Similar results were observed after adjustment for sibship size (Table 3). HLA B27 was
more prevalent among multiplex cases (p=0.0001). Furthermore, the risk allele in the
intergenic region on 21q22 showed a trend towards higher frequency in the multiplex cases
(p=0.08, OR: 1.37, CI (0.96–1.95)). The other susceptibility loci did not show a significant
association with familial occurrence of AS. As shown in Table 3, these results did not
change when the analysis was restricted to patients recruited from the two US cohorts and
covariates were added to reflect population substructure.
The number of risk alleles, an individual carries at non-HLA loci, were added together and
then divided by the total number of successfully genotyped SNPs at the susceptibility loci to
obtain an allelic risk score. This score was regressed against log odds of being from a
multiplex family in order to assess the cumulative effect of the AS non-MHC risk alleles on
the multiplex status. This allelic score was not associated with risk of being from a multiplex
family (p = 0.64).
There was no significant relationship between the number of affected siblings and number of
HLA-B27 alleles (p=0.226, OR: 1.2, 95% CI: 0.89–1.62).
Discussion
The current report is the first genetic study to investigate the frequency of recently described
susceptibility variants in familial and sporadic AS patients. We report that the relative
prevalence of HLA-B27 was higher in familial AS, while the frequency of other risk
variants implicated in AS was not significantly increased. This implies higher genetic load
of HLA-B27 in familial AS patients.
Significant advances have been made in understanding the genetic basis of AS. The most
prominent genetic susceptibility locus remains HLA-B27. Definite non-MHC associations
with AS have been demonstrated with polymorphisms in the ERAP1, IL23R, IL1R2,
ANTXR2 genes in addition to two intergenic regions at chromosome 2p15 and 21q22(2;3).
ERAP1 is the second strongest genetic association after HLA-B27 and the strongest non-
MHC susceptibility locus. IL23R has also been implicated in AS cases of white European
ancestry although not in populations from Eastern Asia. Other genes associated with AS
include IL1R and ANTXR2. Chromosome 2p15 and 21q22 are two intergenic regions or
“gene deserts” associated with AS. Though these non-MHC susceptibility loci were
confirmed in large independent cohorts(2;3), the effect size of these risk variants is
markedly lower than HLA-B27.
The current study compares the genetic data between confirmed familial and sporadic cases
of AS. In addition to the above mentioned non-MHC susceptibility loci, the current study
investigated an MHC susceptibility locus. Evans et al identified a single SNP rs4349859
near the gene MICA which tagged HLA-B27 with sensitivity of 98% and specificity of 99%
in AS cases of white European descent. Thus it can be used as an alternative to HLA-B27
genotyping in this ethnicity (10). We report that the HLA-B27 tag SNP was more prevalent
in familial AS, while we did not observe a significantly higher prevalence of non-MHC
susceptibility loci among familial cases. This implies higher genetic load of HLA-B27 in
familial AS patients. While FDR of AS patients who have the HLA-B27 allele are at higher
risk of developing AS than their HLA-negative counterparts(4), there are no previous reports
of higher frequency of HLA-B27 positivity in familial versus sporadic cases of AS(4). The
current study is the first report that demonstrates higher familial aggregation of AS in
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patients with HLA-B27 positivity. This finding can be explained by the large contribution of
HLA-B27 to susceptibility of AS.
A study of 55 familial and 110 sex and age matched sporadic cases of AS found no
difference in disease onset, age at diagnosis or prevalence of peripheral arthritis or
uveitis(12). Another study of 160 familial and 160 age and sex matched sporadic cases
indicated that familial disease was significantly milder in terms of spinal mobility score,
pain score, psychological and social functioning(13). Differences in frequency of severity
genes were postulated as an explanation for this finding. However, a selection bias towards
milder disease among familial cases is another possible explanation. In the current study, the
familial AS cohorts included a higher percentage of female patients. This might be
secondary to lower threshold of assessing and diagnosing a female patient with AS if
another family member has AS (verification bias). Similar to the above mentioned study
(12), the other clinical features did not differ between the comparison groups.
The strengths of the current study are: the relatively large sample size; strict confirmation of
diagnosis according to the modified New York criteria(6) in index cases as well as affected
FDRs; and the examination of genotype frequencies after correction for sibship size.
Although our study is the largest to date comparing familial AS with sporadic AS, it is still
underpowered to detect more subtle differences in frequency of non-MHC susceptibility
genes between the two investigated groups. Furthermore, we cannot exclude that potential
multiplex cases are misclassified as singleton families because of low number of siblings.
We tried to account for this possible misclassification by adjusting for sibship size. There
are several other potential sources of heritability among familial cases which were not
examined in the current study. There might be further relevant SNPs (either common or rare
variants) or insertion/deletion polymorphisms not tagged by the investigated SNPs.
Moreover, gene-environment interaction might affect familial occurrence of AS.
In summary, HLA tag SNP rs4349859, which tracks closely with HLA-B27, is more
prevalent in familial than sporadic cases of AS. This finding demonstrates higher familial
aggregation of AS in patients with HLA-B27 positivity. The frequency of the recently
described non-MHC susceptibility loci is not markedly different between the sporadic and
familial cases of AS although we cannot exclude more subtle differences in frequency of
these susceptibility variants between the investigated two groups.
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Significance of Innovations
• The first genetic study to compare the frequency of the recently described
susceptibility variants between the familial and sporadic AS cases
• There is a higher frequency of HLA-B27 positivity in familial than sporadic
cases of AS
• The frequency of the other risk variants implicated in AS was not significantly
increased in familial cases, either individually or combined.
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Table 2
Frequency of the AS susceptibility loci in multiplex and singleton cases
SNP Candidate Gene Risk Allele Odds Ratio (95% C.I.) P-value
rs11209026 IL23R G 1.23 (0.64, 2.36) 0.54
rs10865331 2p15* A 0.87 (0.67, 1.12) 0.26
rs2310173 IL1R2 T 1.10 (0.86, 1.42) 0.44
rs4333130 ANTXR2 T 1.15 (0.87, 1.52) 0.32
rs27434 ERAP1 A 0.85 (0.63, 1.13) 0.26
rs2242944 21q22* G 1.20 (0.91, 1.59) 0.19
rs4349859 HLA-B27 tag SNP A 5.41 (2.92, 10.03) 8.4 × 10−8
*
These SNPs are located in the intergenic regions
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